Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Assets (2021 - 2025)

Prime Medicine (PRME) has disclosed Current Assets for 5 consecutive years, with $181.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 14.44% year-over-year to $181.3 million, compared with a TTM value of $181.3 million through Dec 2025, down 14.44%, and an annual FY2025 reading of $181.3 million, down 14.44% over the prior year.
  • Current Assets was $181.3 million for Q4 2025 at Prime Medicine, down from $231.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $296.6 million in Q4 2022 and bottomed at $121.3 million in Q2 2025.
  • Average Current Assets over 5 years is $204.0 million, with a median of $211.9 million recorded in 2024.
  • The sharpest move saw Current Assets tumbled 51.8% in 2023, then skyrocketed 48.2% in 2024.
  • Year by year, Current Assets stood at $270.6 million in 2021, then rose by 9.62% to $296.6 million in 2022, then crashed by 51.8% to $143.0 million in 2023, then surged by 48.2% to $211.9 million in 2024, then fell by 14.44% to $181.3 million in 2025.
  • Business Quant data shows Current Assets for PRME at $181.3 million in Q4 2025, $231.4 million in Q3 2025, and $121.3 million in Q2 2025.